When ADRB2-overexpressing GIST cells were inhibited by a c-KIT inhibitor (imatinib mesylate), it abolished the effect of ADRB2 on promoting ETV1, c-KIT, and p-ERK (Figure 5(b)). Here, ADRB2 is linked to gastrointestinal stromal tumor.